Core Viewpoint - The Hong Kong stock market's innovative drug sector has shown significant growth, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 3.6% and 36 out of 37 covered companies reporting gains, indicating a strong performance in the sector [1] Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a rapid increase of over 3.6% [1] - 36 out of the 37 innovative drug companies covered by the ETF reported positive performance, with Syncona Health-B leading with a surge of over 13% [1] - Major player Kangfang Biologics saw an increase of nearly 5% [1] Group 2: Regulatory Approvals and Developments - Innovent Biologics' CTLA-4 monoclonal antibody "Daboshu" became the first domestically approved CTLA-4 inhibitor, filling a gap in the dual immune new adjuvant therapy field in China [1] - AstraZeneca and Daiichi Sankyo's TROP2 ADC "Dercutuzumab" received approval for breast cancer indications, further solidifying the advantages in the ADC sector [1] Group 3: Industry Trends and Projections - The innovative drug business development (BD) transactions are on the rise, with the total authorization amount for Chinese innovative drugs reaching $135.655 billion and 157 transactions recorded in 2025, both setting historical highs [1] - China's pipeline of new drugs now accounts for 30% of the global total, ranking second worldwide [1] - Analysts suggest that the pharmaceutical and biotechnology industry is entering a critical phase of innovation realization and global expansion, with a potential performance inflection point and valuation restructuring expected by 2026 [1][2] Group 4: Investment Strategies - Huafu Securities maintains that the long-term logic of pharmaceutical innovation remains unchanged, with the recent positive market performance indicating good opportunities for innovative drugs and devices in 2026 [2] - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: pure focus on innovative drugs, significant weight on leading companies, and better risk control [2] - For investors looking to reduce volatility while still focusing on innovative drugs, the only drug ETF (562050) and its associated fund (024986) are recommended, which focus on the top 50 A-share pharmaceutical companies and include a significant portion of traditional Chinese medicine [2][3]

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector has seen a resurgence, with the high-volatility Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 3.6% on January 7, 2023, and 36 out of 37 covered innovative drug companies showing positive performance [1][7]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) quickly surged by 3.61%, reaching a price of 0.545 [2][7]. - Among the covered companies, Tongyu Pharmaceutical-B soared over 13%, while the leading company, Kangfang Biopharmaceutical, increased nearly 5% [1][7]. Group 2: Industry Developments - Innovative drug business development (BD) transactions are continuing to grow, with the total amount of outbound licensing for Chinese innovative drugs expected to reach $135.655 billion by 2025, marking a historical high with 157 transactions [3][9]. - China's pipeline of new drugs currently accounts for 30% of the global total, ranking second worldwide [3][9]. - The biopharmaceutical industry is entering a critical phase of innovation realization and global layout, with a potential performance inflection point and valuation restructuring expected by 2026 [3][9]. Group 3: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated fund (025221) track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drugs, has a high concentration of leading companies (over 73% in the top ten), and has controlled risks by reducing the weight of less liquid stocks [3][9]. - For investors looking to reduce volatility while still focusing on innovative drugs, the only drug ETF in the market (562050) and its associated fund (024986) focus on the top 50 A-share pharmaceutical companies, with approximately 60% in innovative drugs and 25% in traditional Chinese medicine [4][10].